Lixisenatide

Empirical Formula (Hill Notation): C215H347N61O65S

CAS Number: 320367-13-3

Molecular Weight: 4858.49

UNSPSC Code: 51111800

NACRES: NA.77

Lixisenatide is a peptide hormone that belongs to the class of dipeptidyl peptidase-4 inhibitors. It is used in the treatment of type 2 diabetes, including those with a body mass index (BMI) greater than 27 kg/m2 or who have had type 2 diabetes for more than 10 years. Lixisenatide reduces postprandial blood glucose levels by delaying gastric emptying and increasing glucagon-like peptide-1 (GLP-1) release. Lixisenatide has been shown to be effective in reducing cardiovascular events in people with congestive heart failure. Lixisenatide also has water vapor and cardiac effects that are similar to those of GLP-1 agonists.

Product Name: Dulaglutide

Synonyms: Dulaglutide - solution in PBS;Dulaglutide USP/EP/BP;Dulaglutide;Research Grade Dulaglutide(DHE40129);Research Grade Dulaglutide;Dulaglutide (Trulicity;LY2189265);Dulaglutide(sodium salt)

CAS: 923950-08-7

Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist.

Description Dulaglutide, a GLP-1 receptor agonist that is administered subcutaneously once weekly, has been approved since 2014 for the treatment of adults with type 2 diabetes. 

Liraglutide

CAT Number: A000009

CAS Number: 204656-20-2

Molecular Formula: C172H265N43O51

Molecular Weight: 3751.25

Purity: ≥95%

Liraglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist used primarily in the treatment of type 2 diabetes and obesity. By mimicking the action of endogenous GLP-1, liraglutide enhances insulin secretion in response to meals, reduces glucagon levels, and slows gastric emptying, leading to better blood glucose control. It also promotes weight loss by reducing appetite and increasing satiety. Liraglutide has shown additional cardiovascular benefits in patients with diabetes, making it a critical tool in managing both metabolic and cardiovascular risks. It is administered via subcutaneous injection and is well-tolerated in most patients.

Octreotide Acetate (CAS 79517-01-4)

Alternate Names:

D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide Cyclic (2-7)-Disulfide Acetate

Application:

Octreotide Acetate is an octapeptide analog of Somatostatin

CAS Number: 79517-01-4

Molecular Weight: 1079.29

Molecular Formula: C51H70N10O12S2

Somatostatin analogue with antiproliferative effect. It is able to inhibit angiogenesis induced by hepatocellular carcinoma in vivo, and Akt/PKB and telomerase activity of SGC7901 cells.